Atlas FDA

ARCHITECT HAVAB-M Reagent A chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of IgM antib

FDA device recall Z-1596-2010 · posted 2010-05-19 · Terminated

Recall details

Recalling firm
Abbott Diagnostics International, Ltd.
Reason for recall
There is a potential to generate a false grayzone or reactive HAVAB-M result when the ARCHITECT AUSAB assay precedes the ARCHITECT HAVAB-M assay.
Action taken
Direct accounts (hospitals, private laboratories, and other institutions) were sent a Product Correction letter, dated 12/30/2009. The letter identified the affected product, explained the issue and patient impact, and listed several necessary actions. Customers were instructed to follow one of 4 different alternatives to protect the integrity of test results. The letter is to be retained for laboratory records and a copy should be sent to other laboratories that kits were forwarded to. Questions regarding this information should be directed to Customer Service at 1-877-4ABBOTT.
Root cause
Pending
Status
Terminated
Product code
LOL
Quantity affected
1,326
Distribution
Nationwide Distribution -- Including Puerto Rico.
Date initiated
2009-12-30
Date posted
2010-05-19
Date terminated
2011-08-31
Location
Barceloneta, PR

Monitor recalls programmatically

Recalls and clearances share one API, with change alerts when new recalls post.

Related 510(k) clearances

RecordFirmDate
ABBOTT ARCHITECT HAVAB-M (K063329)Abbott Laboratories2007-04-16